[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100599940":3},{"organization":4,"armGroups":7,"interventions":30,"overallOfficials":38,"centralContacts":42,"locations":48,"responsibleParty":258,"collaborators":10,"id":260,"slug":10,"hasResults":261,"nctId":262,"briefTitle":263,"officialTitle":263,"acronym":264,"eligibilityCriteria":265,"healthyVolunteers":261,"sex":266,"minAge":267,"maxAge":268,"enrollmentInfo":269,"targetDuration":272,"studyType":273,"phases":10,"briefSummary":274,"conditions":275,"keywords":277,"overallStatus":51,"whyStopped":10,"lastUpdateSubmitDate":298,"lastUpdatePostDateStruct":299,"startDateStruct":302,"completionDateStruct":304,"leadSponsor":306,"locationsCount":307},{"fullName":5,"class":6},"Novartis","INDUSTRY",[8,14,18,22,26],{"label":9,"type":10,"description":11,"interventionNames":12},"Asciminib",null,"Patients who started their 1L or 2L asciminib following FDA approval on or after Oct-2024 OR Patients who have exited an asciminib interventional study in US for 1L\u002F2L CML and are continuing treatment with asciminib in routine medical care",[13],"Other: TKIs",{"label":15,"type":10,"description":16,"interventionNames":17},"Bosutinib","Patients who started 1L or 2L bosutinib on or after Oct-2021",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"Dasatinib","Patients who started 1L or 2L dasatinib on or after Oct-2021",[13],{"label":23,"type":10,"description":24,"interventionNames":25},"Imatinib","Patients who started 1L or 2L imatinib on or after Oct-2021",[13],{"label":27,"type":10,"description":28,"interventionNames":29},"Nilotinib","Patients who started 1L or 2L nilotinib on or after Oct-2021",[13],[31],{"type":32,"name":33,"description":34,"armGroupLabels":35,"otherNames":36},"OTHER","TKIs","There is no treatment allocation for NIS trials. Patients administered TKI (asciminib, bosutinib, dasatinib, imatinib, nilotinib) by prescription will be enrolled.",[9,15,19,23,27],[37],"Scemblix, Bosulif, Sprycel, Gleevec, Tasigna",[39],{"name":40,"affiliation":40,"role":41},"Novartis Pharmaceuticals","STUDY_DIRECTOR",[43,47],{"name":40,"role":44,"phone":45,"phoneExt":10,"email":46},"CONTACT","1-888-669-6682","novartis.email@novartis.com",{"name":40,"role":44,"phone":10,"phoneExt":10,"email":10},[49,68,83,95,108,123,138,151,163,176,189,204,219,234,248],{"facility":50,"status":51,"city":52,"state":53,"zip":54,"country":55,"cosmosGeoPoint":56,"geoPoint":61,"contacts":62},"University of Alabama at Birmingham","RECRUITING","Birmingham","Alabama","35233-0271","United States",{"type":57,"coordinates":58},"Point",[59,60],-86.80249,33.52066,{"lat":60,"lon":59},[63,65],{"name":10,"role":44,"phone":64,"phoneExt":10,"email":10},"+1 205 502 9967",{"name":66,"role":67,"phone":10,"phoneExt":10,"email":10},"Omer Jamy","PRINCIPAL_INVESTIGATOR",{"facility":69,"status":51,"city":70,"state":71,"zip":72,"country":55,"cosmosGeoPoint":73,"geoPoint":77,"contacts":78},"Stockton Hematology Oncology Medical Group Inc","Stockton","California","95204",{"type":57,"coordinates":74},[75,76],-121.29078,37.9577,{"lat":76,"lon":75},[79,81],{"name":10,"role":44,"phone":80,"phoneExt":10,"email":10},"+1 209 466 2626",{"name":82,"role":67,"phone":10,"phoneExt":10,"email":10},"Ravleen Grewal",{"facility":84,"status":51,"city":85,"state":71,"zip":86,"country":55,"cosmosGeoPoint":87,"geoPoint":91,"contacts":92},"Lundquist Inst BioMed at Harbor","Torrance","90509-2910",{"type":57,"coordinates":88},[89,90],-118.34063,33.83585,{"lat":90,"lon":89},[93],{"name":94,"role":67,"phone":10,"phoneExt":10,"email":10},"Sarah Elizabeth Tomassetti",{"facility":96,"status":51,"city":97,"state":98,"zip":99,"country":55,"cosmosGeoPoint":100,"geoPoint":104,"contacts":105},"Stamford Hospital","Stamford","Connecticut","06902",{"type":57,"coordinates":101},[102,103],-73.53873,41.05343,{"lat":103,"lon":102},[106],{"name":107,"role":67,"phone":10,"phoneExt":10,"email":10},"Joshua Dower",{"facility":109,"status":51,"city":110,"state":111,"zip":112,"country":55,"cosmosGeoPoint":113,"geoPoint":117,"contacts":118},"Sacred Heart Medical Oncology","Pensacola","Florida","32504",{"type":57,"coordinates":114},[115,116],-87.21691,30.42131,{"lat":116,"lon":115},[119,121],{"name":10,"role":44,"phone":120,"phoneExt":10,"email":10},"+1 850 416 2730",{"name":122,"role":67,"phone":10,"phoneExt":10,"email":10},"Dany El-Sayah",{"facility":124,"status":51,"city":125,"state":126,"zip":127,"country":55,"cosmosGeoPoint":128,"geoPoint":132,"contacts":133},"St Agnes Hospital","Baltimore","Maryland","21229",{"type":57,"coordinates":129},[130,131],-76.61219,39.29038,{"lat":131,"lon":130},[134,136],{"name":10,"role":44,"phone":135,"phoneExt":10,"email":10},"+1 410 368 3412",{"name":137,"role":67,"phone":10,"phoneExt":10,"email":10},"Carole Miller",{"facility":139,"status":51,"city":140,"state":141,"zip":142,"country":55,"cosmosGeoPoint":143,"geoPoint":147,"contacts":148},"NY Cancer and Blood Specialists","East Setauket","New York","11733",{"type":57,"coordinates":144},[145,146],-73.10594,40.94149,{"lat":146,"lon":145},[149],{"name":150,"role":67,"phone":10,"phoneExt":10,"email":10},"Adam Hines",{"facility":152,"status":51,"city":153,"state":141,"zip":154,"country":55,"cosmosGeoPoint":155,"geoPoint":159,"contacts":160},"SUNY Upstate Medical University","Syracuse","13210",{"type":57,"coordinates":156},[157,158],-76.14742,43.04812,{"lat":158,"lon":157},[161],{"name":162,"role":67,"phone":10,"phoneExt":10,"email":10},"Gillian Kupakuwana-Suk",{"facility":164,"status":51,"city":165,"state":166,"zip":167,"country":55,"cosmosGeoPoint":168,"geoPoint":172,"contacts":173},"Tri-County Hematology and Oncology Associates","Canton","Ohio","44718",{"type":57,"coordinates":169},[170,171],-81.37845,40.79895,{"lat":171,"lon":170},[174],{"name":175,"role":67,"phone":10,"phoneExt":10,"email":10},"Norman Rafique",{"facility":177,"status":51,"city":178,"state":179,"zip":180,"country":55,"cosmosGeoPoint":181,"geoPoint":185,"contacts":186},"Oregon Oncology Specialists Salem","Salem","Oregon","97301",{"type":57,"coordinates":182},[183,184],-123.0351,44.9429,{"lat":184,"lon":183},[187],{"name":188,"role":67,"phone":10,"phoneExt":10,"email":10},"John Strother",{"facility":190,"status":51,"city":191,"state":192,"zip":193,"country":55,"cosmosGeoPoint":194,"geoPoint":198,"contacts":199},"Avera Cancer","Sioux Falls","South Dakota","57105",{"type":57,"coordinates":195},[196,197],-96.72796,43.54369,{"lat":197,"lon":196},[200,202],{"name":10,"role":44,"phone":201,"phoneExt":10,"email":10},"+1 605 322 3064",{"name":203,"role":67,"phone":10,"phoneExt":10,"email":10},"Tiffani Kirkpatrick",{"facility":205,"status":51,"city":206,"state":207,"zip":208,"country":55,"cosmosGeoPoint":209,"geoPoint":213,"contacts":214},"Baylor Scott and White Research","Temple","Texas","76502",{"type":57,"coordinates":210},[211,212],-97.34278,31.09823,{"lat":212,"lon":211},[215,217],{"name":10,"role":44,"phone":216,"phoneExt":10,"email":10},"+1 254 935 5838",{"name":218,"role":67,"phone":10,"phoneExt":10,"email":10},"Lucas Wong",{"facility":220,"status":51,"city":221,"state":222,"zip":223,"country":55,"cosmosGeoPoint":224,"geoPoint":228,"contacts":229},"Fred Hutchinson Cancer Research Center","Seattle","Washington","98109-1024",{"type":57,"coordinates":225},[226,227],-122.33207,47.60621,{"lat":227,"lon":226},[230,232],{"name":10,"role":44,"phone":231,"phoneExt":10,"email":10},"+1 206 667 7315",{"name":233,"role":67,"phone":10,"phoneExt":10,"email":10},"Vivian Oehler",{"facility":235,"status":51,"city":236,"state":222,"zip":237,"country":55,"cosmosGeoPoint":238,"geoPoint":242,"contacts":243},"MultiCare Health System Institute","Tacoma","98405",{"type":57,"coordinates":239},[240,241],-122.44429,47.25288,{"lat":241,"lon":240},[244,246],{"name":10,"role":44,"phone":245,"phoneExt":10,"email":10},"+1 253 403 5265",{"name":247,"role":67,"phone":10,"phoneExt":10,"email":10},"Nehal Masood",{"facility":249,"status":51,"city":236,"state":222,"zip":237,"country":55,"cosmosGeoPoint":250,"geoPoint":252,"contacts":253},"Northwest Medical Specialties",{"type":57,"coordinates":251},[240,241],{"lat":241,"lon":240},[254,256],{"name":10,"role":44,"phone":255,"phoneExt":10,"email":10},"+1 253 428 8756",{"name":257,"role":67,"phone":10,"phoneExt":10,"email":10},"Ali Dadla",{"type":259,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100599940",false,"NCT07091019","A Real-world Chronic Myelogenous Leukemia (CML) Patient Disease Registry to Describe Patient Experience and Clinical Outcomes Among Patients With CML Receiving Approved First or Second Line Tyrosine Kinase Inhibitor (TKI) Therapy","ASC4REAL-2","Inclusion Criteria:\n\n* 18 years or older at the time of Ph+-CML-CP diagnosis.\n* Receiving TKI treatment (asciminib, bosutinib, dasatinib, imatinib, or nilotinib) in routine medical care either as initial therapy or after 1 prior TKI therapy.\n* Receiving treatment at US and US territories (i.e., Puerto Rico) medical practice (e.g. community-based, office-based, hospital-based, academic).\n* Signed informed consent form (ICF) prior to participation in the study including agreement to be tokenized so that the patient's anonymized RWD (EMRs and\u002For claims data) can be accessed.\n\nExclusion Criteria:\n\n* Active participation in an interventional trial that may influence the management of their Ph+-CML-CP disease.\n* Currently being treated with a CML TKI in 3L or beyond.\n* Known presence of T315I mutation.\n* Currently in TFR phase and are not on active CML TKI therapy.\n* Previously received treatment with a prior stem cell transplant\n* Pregnant or nursing (lactating) female.","ALL","18 Years","100 Years",{"count":270,"type":271},1000,"ESTIMATED","5 Years","OBSERVATIONAL","This CML disease registry (ASC4REAL-2) aims to gather evidence on the tolerability, safety, effectiveness, and patient-reported outcomes (PRO) in real-world healthcare from patients with Ph+-CML-CP treated with TKIs approved for 1L and 2L, including prospective follow-up for 5 years identifying and describing long-term treatment outcomes.",[276],"Chronic Myelogenous Leukemia - Chronic Phase",[278,279,280,281,282,283,284,285,286,287,288,289,290,291,292,293,294,295,296,297],"CML,","CMP-CP,","ASC4REAL,","ASC4REAL-2,","chronic phase,","BCR-ABL, MMR,","TKI,","Tyrosine Kinase Inhibitor,","molecular response,","adult,","registry,","PRO,","patient reported outcome,","QOL,","quality of life,","asciminib,","bosutinib,","imatinib,","nilotinib,","dasatinib","2026-06-22",{"date":300,"type":301},"2026-06-25","ACTUAL",{"date":303,"type":301},"2025-12-17",{"date":305,"type":271},"2033-04-20",{"name":40,"class":6},15]